Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:47 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,620 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Conditions
AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years to 100 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Lucentis in Advanced Macular Degeneration

NCT00896779
Conditions
Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Steven R. Sanislo
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 2.0 aflibercept, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
60
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
Conditions
Advanced Retinitis Pigmentosa
Interventions
AGN-151597
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
4
States / cities
San Francisco, California • Edgewood, Kentucky • Durham, North Carolina + 1 more
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
ForeseeHome
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Palm Beach Gardens, Florida • Baltimore, Maryland • St Louis, Missouri
Conditions
Wet Age Related Macular Degeneration, Wet AMD
Interventions
NT-101 Low Dose, NT-101 High Dose
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more
Completed Phase 1Phase 2 Interventional Results available

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

NCT02317887
Conditions
Retinoschisis, X-Linked
Interventions
RS1 AAV Vector
Biological
Lead sponsor
VegaVect, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Macular Edema
Interventions
NOVA63035 "Corticosteroid"
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Age-related Macular Degeneration
Interventions
small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

NCT03318549
Conditions
Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions
Visual Performance tests, Brain-computer interface
Diagnostic Test · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Inflammation
Interventions
Intravitreal Ketorolac
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Retinitis Pigmentosa
Interventions
Low Dose NT-501, High Dose NT-501
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 68 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
Conditions
Macular Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
Conditions
Age-Related Macular Degeneration
Interventions
DE-120
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Bakersfield, California • Beverly Hills, California • Dallas, Texas
Conditions
Exudative Age-Related Macular Degeneration
Interventions
AL-78898A, Ranibizumab
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Assessment of Novel Intraocular Injection Guide

NCT02315170
Conditions
Retinal Disease
Interventions
intraocular injection guide, standard lid speculum
Device
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 15 more